Irritable bowel syndrome, chronic itching, asthma and migraine are in many cases hard-to-treat conditions. They have in ...

Presentations will be delivered by experts from a wide variety of leading research groups including Pfizer, GSK, and Bio-Techne, along with co-hosts IPA, ACROBiosystems, and Curia. SALT LAKE CITY, ...

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

GenAI offers a realistic path forward in tackling previously undruggable targets, with the potential to reshape the entire ...

The in-licensed antibody represents what iBio believes to be the first functional inhibitor of Activin E, a challenging, yet genetically validated therapeutic target playing a key role in regulating ...

Expanded collaboration leverages complementary expertise to unlock next-generation oncology therapeutics Focus on breakthrough ADC payloads and ...

Single and multi-dose studies of the small molecule TREM2 agonist VG-3927 clear early safety hurdle. Meanwhile, new findings ...

Another reason for choosing a particular modality is that it is a team’s specialty. Strategic choices can be less about determining which modality best fits a potential target than about choosing a ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

It binds both transmembrane and soluble TREM2, triggering a rise in CSF sTREM2. Single and multi-dose studies of the small ...